Physician profile
Michael P Cooper
NPI 1386059277
$8,009.56
in general payments reported to CMS, 2019-2025
28 companies · $607 in 2025
The $607 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $1,177 · 2021: $2,430 · 2022: $1,920 · 2023: $1,109 · 2024: $21.50 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.55 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,058.88 | 2019-2025 | Trintellix |
| Abbvie INC. | $1,007.33 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $726.53 | 2019-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $690.41 | 2019-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $657.33 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $643.87 | 2020-2025 | Ingrezza |
| Lundbeck LLC | $596.90 | 2019-2025 | Rexulti |
| Allergan, INC. | $418.90 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $397.59 | 2019-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $315.02 | 2021-2025 | Qelbree, Qelbree |
| Avanir Pharmaceuticals, INC. | $276.95 | 2019-2022 | |
| Eisai INC. | $241.73 | 2020-2021 | |
| Alkermes, INC. | $157.29 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Merck Sharp & Dohme LLC | $134.24 | 2021-2023 | Belsomra |
| Axsome Therapeutics, INC. | $94.92 | 2022-2025 | Auvelity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $85.20 | 2021-2023 | Azstarys |
| Tris Pharma INC | $82.59 | 2020-2023 | Dyanavel Xr |
| Shire North American Group INC | $71.25 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $70.23 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $54.31 | 2022-2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $49.72 | 2022-2024 | Uzedy, Austedo Xr |
| Bausch Health US, LLC | $49.35 | 2022-2023 | Wellbutrin, Aplenzin |
| Almatica Pharma LLC | $38.20 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $24.18 | 2022 | |
| Sunovion Pharmaceuticals INC. | $23.74 | 2020 | |
| Ironshore Pharmaceuticals INC. | $17.37 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.26 | 2019 | |
| Indivior INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.